tbuckley/cabot-search huggingface dataset:
AB0239 Rasch Analysis of the Therapeutic Alliance Questionnaire for Rheumatic Diseases (TAQRDIS) in Patients with Gout and Rheumatoid Arthritis (RA)
Authors: E. Alvarez-Hernandez, L.D. Upegui-Arango, J. Vazquez-Mellado, E. Aranda-Arreola, R. Burgos-Vargas, I. Pelaez-Ballestas
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> TAQRDis is an instrument to measure the therapeutic alliance in rheumatic patients developed and validated in our department. Despite TAQDRDis performs well, we found some limitations that may be overcome Rasch analysis. <h3>Objectives</h3> To validate TAQRDis in patients with RA or gout using Rasch analysis. <h3>Methods</h3> The questionnaire was administered to two cohorts of patients, one with gout (GRESGO) and another with RA (RECAR) to collect sociodemographic, clinical, and therapeutic data. Instrument description: TAQRDis includes 21 questions (9 for therapeutic adherence and 12 for patient-physician9s relationship) with 34 items. The correlation betweem TAQRDis and other adherence questionnaires (MASRI, HAQ-DI, and EuroQoL 5D) was satisfactory. Estimation of Cronbach9s α and major component analysis was performed. For Rasch analysis we estimated separation and reliability rates, fit statistics separation person-item and dimensionality statistics components analysis, infit and outfit rates and Wright map). We used Stata v11 and WinSteps v3.73 software. <h3>Results</h3> 238 patients with gout (age 47.6±13 years, 95% males, education 9.2±4.2 years, socioeconomical level index 8.44±2.11) and 50 with RA (94% female, age 45±14 years, education 8.6±3 years, socioeconomic level index 14.0±1) were included. Cronbach9s α value was 0.75. eighty percent of the variance accounted for 6 of the 34 items. We found an item separation index of 6.26 for gout and 2.19 four RA, and a person separation index of 0.17 for gout and 1.79 for RA. Item reliability was 0.98 for gout and 0.83 for RA. Mean-data adjustment-ranges comparing the observed vs. the expected pattern were 0.93 for gout and 0.97 for RA for infit (weighted item and person behavior), and 1.05 for gout and 0.94 for RA for outfit (sensitive to outliers). Uni-dimensional analysis showed an explained total variance of 148% in patients with gout and 62% with RA; unexplained variance was 2.5% and 6.5% for gout and RA. In the alliance tested for both groups, 88% of items showed loads between 0.5 and -0.5 (optimal), whereas the extent of difficulty lied between 3.98 and -4.5 logit for gout and 3.63 and -2.08 for RA. <h3>Conclusions</h3> According to the ideal model out forward by Rasch, TAQRDis has good discrimination and adjustment in measuring the therapeutic alliance. Patients with RA were more consistent in their responses. The use of Rasch analysis is recommended to validate outcome measures from the patient9s perspective. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.3344
AB0169 IL-2 Therapy Decreases Total Number of Kidney Infiltrating CD4+ T Cells and Reduces the Cellular Activity of CD4+ Effector T Cells in NZB/W Mice
Authors: A. Rose, C. von Spee-Mayer, L. Kloke, J. Humrich, G. Riemekasten
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by an acquired IL-2 deficiency, which leads to a homeostatic imbalance between regulatory T cells (Treg) and effector T cells (Tcon) (Humrich et al. 2010). We recently demonstrated that Treg homeostasis in lymphoid organs of diseased (NZBxNZW) F1 mice can be restored by treatment with recombinant IL-2 (IL-2) resulting in an amelioration of kidney disease. <h3>Objectives</h3> The aim of this study was to investigate the impact of IL-2 therapy on intrarenal Foxp3+ Treg and kidney infiltrating conventional CD4+ T cells (Tcon) in the (NZBxNZW) F1 mouse model of lupus nephritis. <h3>Methods</h3> (NZBxNZW) F1 mice with active nephritis were treated with recombinant IL-2 either for a short period of 5 days or for a longer period of 30 days in total. Absolute numbers, phenotype and proliferation of kidney infiltrating CD4+ T cell subsets were determined by flow cytometry at different time points. <h3>Results</h3> Short-term IL-2 treatment resulted in an enhanced cellular activity and frequencies of intrarenal CD4+Foxp3+ Treg compared to untreated age-matched control mice. Furthermore, long-term IL-2 treatment significantly reduced total numbers of kidney-infiltrating CD4+ T cells (p=0,027) and reduced the frequency of intrarenal Foxp3+ Treg (p=0,002). Furthermore, CD4+ Tcon with a memory/effector phenotype showed markedly reduced signs of cellular activation. <h3>Conclusions</h3> Our data indicate that short-term IL-2 treatment is able to expand the size of the intrarenal Treg pool. In contrast, long-term IL-2 treatment decreases the frequency of kidney-infiltrating memory/effector T cells and reduces cellular hyperactivity of Tcon, suggesting that Treg suppress the activation and expansion of kidney-infiltrating Tcon. These results may in part explain the amelioration of disease induced by treatment with IL-2 and underline the important role of intrarenal Treg for the suppression of kidney disease in lupus mice. These results also provide additional important rationales for an IL-2 based immunotherapy of human disease. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.5582
Abstract 5089: Comparison of treatment results between two fractionation schedules of high-dose-rate intracavitary brachytherapy (HDR-ICBT) in patients with cervical cancer: A prospective cohort study
Authors: Eng-Yen Huang, Chong-Jong Wang
Journal: Cancer Research (2011)

Abstract Purpose: To compare the treatment results of two fractionation schedules for high-dose-rate intracavitary brachytherapy (HDR-ICBT) in patients with cervical cancer. Materials and Methods: From June 2001 through December 2008, 321 patients with Stage IB-IVA cervical cancer were enrolled in the study. All patients underwent pelvic irradiation and HDR-ICBT. The median central dose and parametrial dose were 39.6 Gy and 45 Gy, respectively. Patient underwent either 6 Gy × 4 (HDR-4) (n=168) or 4.5 Gy × 6 (HDR-6) (n=153) to point A of ICBT twice per week. The biologically effective doses (BED) of point A were 38.4 and 39.15 Gy10 in HDR-4 and HDR-6 group, respectively. The rates of overall survival, local control, distant failure, proctitis, cystitis, and enterocolitis were compared between HDR-4 and HDR-6. Results: There were no significant differences of demographic data between HDR-4 and HDR-6 except of total treatment time. The median follow-up time was 40.6 months (range 1.7-95.4). The 5-year proctitis rates were 21.7% and 22.3% in HDR-4 and HDR-6 (p = 0.417), respectively. The corresponding rates of Grade 2-4 proctitis were 15.9% and 9.7% (p = 0.120). The corresponding rates of Grade 3-4 proctitis were 4.3% and 3.1% (p = 0.804). Subgroup analysis in patients with age ≥ 63 years revealed that 5-year Grade 2-4 proctitis rates were 23.4% and 5.5% (p = 0.013) in HDR-4 and HDR-6, respectively. The corresponding rates in patients with age &amp;lt; 63 years were 8.3% and 13.4% (p = 0.659). The rates of overall survival, local control, distant failure, cystitis, and enterocolitis were not significantly different between HDR-4 and HDR-6. Conclusion: Small fraction size of HDR-ICBT decreases Grade 2-4 proctitis in elderly patients. The schedule is suggested in those patients who tolerate additional two applications of HDR-ICBT. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 5089. doi:10.1158/1538-7445.AM2011-5089
Quantitative Nitroblue Tetrazolium Test in Chronic Granulomatous Disease
Authors: Robert L. Baehner, David G. Nathan
Journal: New England Journal of Medicine (1968)

Chronic granulomatous disease is an X-linked defect in the killing of certain bacteria by peripheral blood granulocytes and may be detected with the nitroblue tetrazolium (NBT) test. The rate of reduction of NBT by normal leukocytes is stimulated by phagocytosis. It also depends on cell number, pH and temperature. Granulocytes of affected male patients failed to reduce NBT to blue formazan during phagocytosis whereas leukocytes of carrier females, usually asymptomatic, demonstrated intermediate dye reduction. A 17year-old girl, who had lifelong recurrent suppurative infections, was identified as having chronic granulomatous disease by the NBT test. Her leukocytes and those of affected males had absent dye reduction, low values for oxygen consumption and diminished NADH oxidase activities during phagocytosis. Her parents' leukocytes had normal dye reduction rather than the intermediate values noted in mothers of affected males. Thus, the disease may also be transmitted as an autosomal recessive trait.
Recurrent Ovarian Carcinoma Presenting as a Solitary Sternal Metastasis on FDG PET/CT
Authors: Linh Ho, Aarti Kaushik, Weifang Zhang, Heidi Wassef
Journal: Clinical Nuclear Medicine (2011)

We report the positron emission tomography/computed tomography appearance of solitary sternal metastasis from primary ovarian carcinoma in a 65-year-old woman who underwent surgery followed by chemoradiation treatment 3 years earlier. Restaging positron emission tomography/computed tomography study demonstrates an intensely active destructive lesion involving the entire sternum (maximum standard uptake value: 4.7) with a photopenic soft tissue mass component in the center of the sternum protruding anteriorly suggestive of necrosis. This sternal lesion was subsequently biopsied and pathology revealed metastatic disease from the primary ovarian tumor for which the patient had received chemoradiation therapy. Bone involvement in ovarian cancer is relatively rare and even rarer in the sternum.
THU0294 Pulmonary Arterial Hypertension Complicating Primary Sjogren Syndrome: A Rare Association
Authors: B. M. Lynch, V. Sobanski, C. E. Handler, B. E. Schreiber, C. P. Denton, J. G. Coghlan
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Primary Sjögren Syndrome (pSS) has an estimated prevalence of 0.2%. Connective tissue disorders are known risk factors for causing pulmonary arterial hypertension (PAH). The association of PAH and pSS is rare. <h3>Objectives</h3> To examine the incidence of PAH in pSS and to review the clinical, hemodynamic parameters and medical management of each case. <h3>Methods</h3> We included 1,036 patients followed in a specialist Pulmonary Hypertension Centre between 1996-2010. History of appetite suppressant intake, thyroid hormone level and human immunodeficiency virus (HIV) serology were collected to rule out other causes of PAH. Cardiac echo-doppler excluded congenital heart disease. A ventilation/perfusion lung scan, a spiral computed tomography of the chest, and a pulmonary angiography if necessary were performed to exclude chronic thromboembolic pulmonary hypertension. Of 1036 patients, 79% had systemic sclerosis, 7% had SLE, 5% had mixed connective tissue disease, 2.5% had undifferentiated connective tissue disease, 2% had myositis and the remainder had overlap diseases. Seven patients (&lt;1%) fulfilled the 2002 revised criteria for pSS proposed by the American-European Concensus group. All patients with secondary SS were excluded. In 7 patients with pSS who underwent a right heart catherisation (RHC), 4 patients had PAH (mean pulmonary arterial pressure ≥25mmHg and pulmonary capillary wedge pressure &lt;15mmHg), 1 patient had post capillary pulmonary hypertension (mean pulmonary arterial pressure ≥25mmHg and pulmonary capillary wedge pressure &gt;15mmHg) and 2 patients did not have pulmonary hypertension. <h3>Results</h3> All patients with pSS and PAH were female with a mean age at PAH diagnosis of 61.8 ± 10.8 years. Clinical presentation of PAH was severe in all cases: WHO functional class (FC) was III in patients 1-3 and IV in patient 4. Mean 6-minute walk distance was 310 ± 105m (range, 152-448m). Overall, PAH was severe with a mean mPAP of 51 ± 12mmHg. Among the 4 patients, patients 1 and 2 received Bosentan therapy alone, patient 3 received a combination of Bosentan and Sildenafil and patient 4 received inhaled Iloprost alone. Patient 4 did not have a repeat RHC at 3-4 months. The remaining three patients showed a reduction in mPAP with no change in WHO FC at 3-4 months (Table 1). Two patients died from PAH at 35 (patient 2) and 26 (patient 4) months after diagnosis. <h3>Conclusions</h3> PAH in pSS is rare and to our knowledge, there are less than 50 published case reports in the English literature. We report a case series of four patients with pSS and PAH over 14 years in a specialist pulmonary hypertension centre. Standard PAH therapies (endothelin receptor antagonists, phosphodiesterase type 5 inhibitors or prostanoids) were initially effective but the best treatment strategy remains to be defined. <h3>Disclosure of Interest</h3> None Declared
Case 76-1963
Authors: Conger Williams, Benjamin Castleman
Journal: New England Journal of Medicine (1963)

Presentation of CaseA seventy-five-year-old woman entered the hospital because of dyspnea.The patient had been in good health until two and a half years previously, when resection of the splenic flexure for adenocarcinoma was done at another hospital. The lymph nodes and resection margins were free of tumor. A colostomy was performed and was closed uneventfully several months later. One year later edema developed, and digitalis and periodic injections were given. Several months before entry she became dyspneic and thereafter was admitted four times to another hospital, where repeated thoracenteses were performed. The urine gave + + to + . . .
810 A NOVEL ROLE OF CD147 IN IMMUNE CELL AGGREGATION AND INFLAMMATION ASSOCIATED TISSUE INJURY
Authors: A.J. Morgan, S.R. Calabro, A.J. Potter, T.J. Iemma, V.W. Wen, C.M. Fernández, C. Yee, D.G. Bowen, G.W. McCaughan, F.J. Warner, S.V. McLennan, N.A. Shackel
Journal: Journal of Hepatology (2012)
A novel differentiation-inducing therapy for acute promyelocytic leukemia with a combination of arsenic trioxide and GM-CSF
Authors: A Muto, M Kizaki, C Kawamura, H Matsushita, Y Fukuchi, A Umezawa, T Yamada, J Hata, N Hozumi, K Yamato, M Ito, Y Ueyama, Y Ikeda
Journal: Leukemia (2001)
ESTUDIO PROSPECTIVO ALEATORIZADO COMPARANDO PILLCAM SB VS MIROCAM
Authors: JR Aparicio, J Martínez, F Ruiz, JA Casellas
Journal: Endoscopy (2010)

Introducción: El 20% de las exploraciones con cápsula endoscópica (CE) son incompletas. Recientemente han aparecido en el mercado otras CE como la MiroCam (IntroMedic), que ofrecen una mayor duración de exploración (hasta 12 horas). Nuestra hipótesis es que con una mayor duración de la exploración, el tanto por ciento de exploraciones completas sería mayor.
Pulmonary Embolism
Authors: Paul M. Kemp, David S. Tarver, Vincent Batty, Valerie Lewington
Journal: Clinical Nuclear Medicine (1996)

Pulmonary embolism is commonly fatal, yet notoriously difficult to detect. Diagnosis often relies on the ventilation-perfusion radionuclide scan, which itself is frequently equivocal. It has been suggested that if the equivocal ventilation-perfusion scan is interpreted in the light of clinical information, diagnostic accuracy can be improved. However, which features in the history should be considered? In this study of 197 patients undergoing ventilation-perfusion scanning, the clinical data of the 98 patients with either high-probability or normal scans were compared to the scan findings. The presence of a deep vein thrombosis was significantly associated with a high probability scan, whereas the presence of constant chest pain was significantly associated with a negative scan. Classical symptoms for pulmonary embolism, namely pleuritic chest pain and hemoptysis, were poor predictors of high-probability scans. Consequently, the authors advise considerable caution when using the clinical data to aid the interpretation of the equivocal lung scan in the individual case.
FRI0503 Can ultrasonographic findings predict response to tumor necrosis factor-a inhibitor treatment in rheumatoid arthritis?
Authors: N. Inanc, G. Ozen, H. Direskeneli
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Tumor necrosis factor-α inhibitors (TNFi) are highly effective in patients with rheumatoid arthritis (RA), while not effective in all, with predictors of response being necessary. Although genetic, inflammatory and serologic biomarkers are under major investigation for this purpose, little is known about the predictive value of ultrasonographic parameters in RA. <h3>Objectives</h3> To investigate the ability of ultrasonographic parameters to predict which patients with RA will benefit from the treatment with TNFi in terms of EULAR response. <h3>Methods</h3> Biologic naive RA patients starting treatment with TNFi were examined longitudinally by ultrasonography (US) (both Gray-Scale [GS] and Power Doppler [PD]) of 28 joints according to standard scans of EULAR guideline and clinically (tender/swollen joint counts, DAS28 and HAQ scores) at baseline and after 3 months. US examinations were performed by an experienced sonographer (NI) using a MyLab 70 US machine (Esaote, Italy) equipped with 6-18 and 4-13 MHz broad band multi-frequency linear transducer. US synovitis and PD signals were semiquantitatively graded from 0 to 3. Total PD and synovitis scores of all sites are recorded as sum scores of PD and GS, respectively. The clinical response was evaluated according to the EULAR response criteria at 3<sup>rd</sup> month. Potential ultrasonographic predictors of response were identified using multivariate binary logistic regression models. <h3>Results</h3> The study cohort consisted of 42 RA patients (F/M=33/9, mean age 49.0±10.7 years) with a mean disease duration of 9.1±7.5 years and mean baseline DAS28 score of 5.5±1.0. Rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibody (CCP) positivity were 76.2% and 64.3%, respectively. Baseline characteristics of TNFi responders (30/42) and non-responders (12/42) are shown in Table 1. Swollen joint count (p= 0.05), sum scores of baseline PD (p= 0.048), GS (p= 0.048) and PD+GS (p= 0.046) differed significantly between responders and non-responders. Baseline PD sum score was the only ultrasonographic parameter in the multivariate analysis predicting which patients achieve good/moderate EULAR response with TNFi at 3<sup>rd</sup> month (p= 0.004). <h3>Conclusions</h3> Our data underline that baseline PD scores, despite similar clinical features, can predict which patients will respond to TNFi therapy. <h3>Disclosure of Interest</h3> None Declared
Fasciola hepatica as an uncommon cause of cholangitis
Authors: Daniel Popa, Ivan Jovanovic, Dejan Radenkovic
Journal: Endoscopy (2014)

A 45-year-old man with fever, jaundice, and right upper quadrant abdominal pain was referred to our Clinic for emergency decompression of the biliary tract owing to acute cholangitis. Laboratory data showed elevated liver enzymes: alkaline phosphatase, 490 IU/L; gamma-glutamyl transpeptidase, 1685 IU/L; alanine aminotransferase, 260 IU/L; aspartate aminotransferase, 195 IU/L; total bilirubin level, 360 IU/L (reference range: 0 – 20.5 IU/L); leukocytosis, 13.5 × 109/L.
Stat Bite U.S. Cancer Mortality Trends by Age: Comparison of 1973/74 to 1987/88
Authors: B. K. Edwards
Journal: JNCI Journal of the National Cancer Institute (1991)

Journal Article Stat Bite U.S. Cancer Mortality Trends by Age : Comparison of 1973/74 to 1987/88 Get access Brenda K. Edwards, PhD. Brenda K. Edwards, PhD. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 83, Issue 12, 19 June 1991, Page 811, https://doi.org/10.1093/jnci/83.12.811 Published: 19 June 1991
3D ANALYSIS OF MYOCARDIAL PERFUSION FROM REGADENOSON STRESS COMPUTED TOMOGRAPHY: CAN ACCURACY BE IMPROVED BY ITERATIVE RECONSTRUCTION?
Authors: Victor Mor-Avi, Nicole M. Bhave, Nadjia Kachenoura, Benjamin H. Freed, Michael Vannier, Barbara Newby, Karin Dill, Roberto M. Lang, Amit R. Patel
Journal: Journal of the American College of Cardiology (2013)
“Scar-cinoma”: viewing the fibrotic lung mesenchymal cell in the context of cancer biology
Authors: Jeffrey C. Horowitz, John J. Osterholzer, Antonia Marazioti, Georgios T. Stathopoulos
Journal: European Respiratory Journal (2016)

Lung cancer and pulmonary fibrosis are common, yet distinct, pathological processes that represent urgent unmet medical needs. Striking clinical and mechanistic parallels exist between these distinct disease entities. The goal of this article is to examine lung fibrosis from the perspective of cancer-associated phenotypic hallmarks, to discuss areas of mechanistic overlap and distinction, and to highlight profibrotic mechanisms that contribute to carcinogenesis. Ultimately, we speculate that such comparisons might identify opportunities to leverage our current understanding of the pathobiology of each disease process in order to advance novel therapeutic approaches for both. We anticipate that such “outside the box” concepts could be translated to a more precise and individualised approach to fibrotic diseases of the lung.